.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
US Department of Justice
Accenture
Covington
Novartis
Citi
Boehringer Ingelheim
Express Scripts
Medtronic

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,058,291

« Back to Dashboard

Which drugs does patent 8,058,291 protect, and when does it expire?


Patent 8,058,291 protects NAMZARIC and is included in one NDA. There have been three Paragraph IV challenges on Namzaric.

This patent has fifty-seven patent family members in eighteen countries.

Summary for Patent: 8,058,291

Title:Methods and compositions for the treatment of CNS-related conditions
Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:11/399,879
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► SubscribeMEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE► Subscribe
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-001Dec 23, 2014ABRXYesNo► Subscribe► SubscribeMEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE► Subscribe
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-004Jul 18, 2016RXYesNo► Subscribe► SubscribeMEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE► Subscribe
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-002Dec 23, 2014ABRXYesYes► Subscribe► SubscribeMEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,058,291

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,794Methods and compositions for the treatment of CNS-related conditions► Subscribe
8,426,472Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
2,012,045,508► Subscribe
8,329,752Composition for administering an NMDA receptor antagonist to a subject► Subscribe
8,580,858Compositions for the treatment of CNS-related conditions► Subscribe
8,338,485Compositions for the treatment of CNS-related conditions► Subscribe
8,283,379Methods and compositions for the treatment of CNS-related conditions► Subscribe
8,168,209Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
8,338,486Methods for the treatment of CNS-related conditions► Subscribe
8,173,708Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,058,291

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore157415► Subscribe
Russian Federation2007140348► Subscribe
Russian Federation2404750► Subscribe
Russian Federation2007122410► Subscribe
Mexico2007012374► Subscribe
Mexico2007006120► Subscribe
South Korea20060124731► Subscribe
South Korea101406456► Subscribe
South Korea20070116996► Subscribe
South Korea101301429► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cipla
Queensland Health
Citi
AstraZeneca
Boehringer Ingelheim
Moodys
Chubb
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot